New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
10:57 EDTEWC, TRMB, ECA, ETRM, AFL, ZTSHigh option volume stocks: ETRM TRMB ZTS ECA EWC AFL
News For ETRM;TRMB;ZTS;ECA;EWC;AFL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2015
16:22 EDTAFLAflac reports Japan Q2 operating EPS declined 8.9% on currency-neutral basis
"In yen terms, Aflac Japan's premium income declined 1.2% in Q2. Net investment income increased 5.7%. Investment income growth was magnified by the weaker yen/dollar exchange rate because approximately 49% of Aflac Japan's Q2 investment income was dollar-denominated, compared with 46% a year ago. Total revenues were flat in Q2. The pretax operating profit margin decreased to 21.1% from 21.7% in the prior year. Pretax operating earnings in yen decreased 3.1% on a reported basis and decreased 8.9% on a currency-neutral basis. For the first half of the year, premium income in yen decreased .5%, and net investment income rose 6.5%. Total revenues in yen were up .6%, and pretax operating earnings fell .6%," said the company.
16:20 EDTAFLAflac sees FY15 operating EPS $5.88-$6.17, consensus $5.97
Subscribe for More Information
16:19 EDTAFLAflac sees Q3 EPS $1.40-$1.53, consensus $1.48
Subscribe for More Information
16:14 EDTAFLAflac reports Q2 operating EPS $1.50, consensus $1.52
Reports Q2 revenue $5.29B, consensus $5.24B.
15:21 EDTAFLNotable companies reporting after market close
Subscribe for More Information
July 27, 2015
06:35 EDTTRMBAGCO, Trimble announce collaboration
Subscribe for More Information
July 24, 2015
06:09 EDTECAEncana on track to deliver FY15 cash flow guidance of $1.4B-$1.6B
Encana remains on track to deliver its 2015 cash flow guidance of between $1.4B-$1.6B. The company generated second quarter cash flow of $181M or 22c per share; an operating loss of $167M or 20c per share; and a net loss of $1.6B or $1.91 per share primarily due to a $1.3B non-cash, after-tax ceiling test impairment. Year-to-date, Encana has generated $676M in cash flow or 85c per share; an operating loss of $148M or 19c per share; and net loss of approximately $3.3B or $4.15 per share, largely attributable to non-cash, after-tax ceiling test impairments of $2.6B. Encana is on track to fully fund its 2015 capital program and dividend with anticipated cash flow and the proceeds from previously announced and completed divestitures. In addition, the company continued streamlining its organization during the second quarter to align its structure with its transformed portfolio and disciplined capital program.
06:08 EDTECAEncana on track for average Q4 production of 50,000 BOE/d
06:07 EDTECAEncana reports Q2 EPS (20c), consensus (15c)
Subscribe for More Information
July 23, 2015
15:05 EDTECANotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include AbbVie (ABBV), consensus $1.06... Biogen (BIIB), consensus $4.10... Simon Property Group (SPG), consensus $2.36... State Street (STT), consensus $1.37... V.F. Corp. (VFC), consensus 36c... Johnson Controls (JCI), consensus 91c... American Airlines (AAL), consensus $2.60... Rockwell Collins (COL), consensus $1.30... Cabot Oil & Gas (COG), consensus 4c... Lear (LEA), consensus $2.48... Encana (ECA), consensus (15c).
July 22, 2015
08:11 EDTECAEncana shares compelling, says Morgan Stanley
Subscribe for More Information
July 21, 2015
16:25 EDTZTSZoetis files automatic mixed securities shelf
Subscribe for More Information
06:58 EDTZTSZoetis added to US 1 List at BofA/Merrill
July 20, 2015
08:38 EDTZTSAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:30 EDTZTSZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
July 17, 2015
10:03 EDTEWCHigh option volume stocks
High option volume stocks: EWC DF WPX CLSN TE CMA SWI CE VRSN USG
July 16, 2015
08:54 EDTAFLBofA/Merrill U.S. life insurance analyst holds analyst/industry conference call
U.S. Life Insurance Analyst Weiss, along with Jill Hoffman, VP of Government Affairs and Felicia Smith, VP & Senior Counsel for Regulatory Affairs from the Financial Services Roundtable, discuss the Labor Department's recent proposal to impose fiduciary standards on the sale of retirement products on an Analyst/Industry conference call to be held on July 20 at 11 am.
07:08 EDTETRMEnteroMedics' vBloc therapy shows sustained weight loss at 18 months
EnteroMedics announced that 18 month results from the company's ReCharge Clinical Study published in the Journal of Obesity highlights sustained weight loss in patients receiving vBloc Neurometabolic Therapy. Results at 18 months from the ReCharge Study demonstrate both the sustainability of weight loss using vBloc Therapy and the safety profile of the device over time. The ReCharge Pivotal Trial is a randomized, double-blind, sham-controlled, multicenter pivotal clinical trial of vBloc Neurometabolic Therapy in 239 patients with obesity. At 18 months, the gap between the vBloc Therapy Group and the Sham group widened, with the vBloc Therapy group sustaining their weight loss at 23.5% EWL, compared to a significant excess weight regain in the Sham control group which had dropped to 10.2% EWL at the same time point. The safety profile of vBloc Therapy remained favorable at 18 months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use